This review discusses the evidence for endocrine treatment in postmenopausal patients with metastatic breast cancer. First line treatment with non-steroid aromatase inhibitors (AI) yields response rates of 30% and improves progression free survival, but not overall survival, compared to tamoxifen. With second line treatment using steroid AI, estrogen antagonists or selective estrogen receptor modulators prolonged disease stabilisation is achieved in 40% of patients. With third line treatment using steroid AI and estrogen antagonists disease stabilisation is achieved in up to 30% of patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
treatment postmenopausal
8
postmenopausal patients
8
patients metastatic
8
metastatic breast
8
treatment steroid
8
steroid estrogen
8
estrogen antagonists
8
disease stabilisation
8
stabilisation achieved
8
[antiestrogen treatment
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!